BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Braeburn Pharma Release: Phase II Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder

  June 23, 2017

   · 

  5 min read
• Samsung Bioepis’ Imraldi (Adalimumab) Recommended For Approval By EMA

  June 23, 2017

   · 

  2 min read
• Drug Development

  bluebird bio Announces Early Data From Phase III Northstar-2 (HGB-207) Study Of LentiGlobin Drug Product At European Hematology Association Annual Meeting

  June 23, 2017

   · 

  7 min read
• Genetown

  Acceleron Pharma Provides Updated Results From Phase II Studies Of Luspatercept In Beta-Thalassemia At The 22nd Congress Of The European Hematology Association

  June 23, 2017

   · 

  8 min read
• FDA

  BioDelivery Announces Health Canada Approval Of BELBUCA

  June 23, 2017

   · 

  17 min read
• Drug Development

  Syros Pharma Presents Data At EHA Supporting Potential Of SY-1425, Its First-In-Class Selective Rara Agonist, In Genomically Defined AML And MDS Patients

  June 23, 2017

   · 

  8 min read
• Biogen’s IMRALDI, An Adalimumab Biosimilar Candidate Referencing Humira, Granted Positive Opinion By Committee For Medicinal Products For Human Use

  June 23, 2017

   · 

  5 min read
• Drug Development

  Novartis AG Pivotal CTL019 6-Month Follow-Up Data Show Durable Remission Rates In Children, Young Adults With R/R B-Cell ALL

  June 23, 2017

   · 

  11 min read
• BioMidwest

  AbbVie Receives CHMP Positive Opinion For MAVIRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

  June 23, 2017

   · 

  6 min read
• Drug Development

  The Lancet Oncology Publishes Anti-Leukemic Activity And Safety Data For Gilteritinib In Relapsed/Refractory Acute Myeloid Leukemia

  June 23, 2017

   · 

  4 min read